Compare BridgeBio Pharma Inc (BBIO) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Xpeng Inc - ADR — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Xpeng Inc - ADR trades at $11.77 (market cap $11.15B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| BBIO | XPEV | |
|---|---|---|
Market Cap | $16.36B | $11.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $28.07 |
52-Week Low | $47.29 | $11.68 |
Enterprise Value | $18.14B | $13.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XPeng (XPEV) trades at $12.00, down 1.07% on the day, with a bearish technical signal. The company reported Q1 2026 revenue of $76.72 billion but a net loss of $1.14 billion, though the net margin improved to -1.49% from -14.17% in 2024. Recent news highlights vehicle delivery growth, international expansion, and advancements in autonomous driving technology.
The outlook is mixed: strong revenue growth and analyst buy ratings (64.7% consensus) suggest upside to the $17.00 price target, but persistent losses, high EV/EBITDA of 40.09, and competitive pressures pose risks. Investor sentiment is cautious amid earnings volatility and macroeconomic headwinds in the EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
